Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -66.2%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $8M | $33M | $66M | $431M | $844M | $328M | $315456 | $631942 | — | — |
| Enterprise Value | $8M | $12M | $51M | $127M | $437M | $830M | $305M | $3M | $-6861413 | — | — |
| P/E Ratio → | -0.24 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.13 | 0.29 | 1.07 | 1.82 | 15.49 | 46.95 | 38.52 | 0.03 | 0.05 | — | — |
| P/B Ratio | 0.14 | 0.19 | 0.93 | 0.68 | 1.73 | 2.50 | 9.34 | 0.09 | 0.06 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.43 | 1.66 | 3.52 | 15.73 | 46.17 | 35.92 | 0.30 | -0.57 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 22.0% | 22.0% | 1.2% | 26.5% | 21.4% | 21.5% | 32.6% | 33.2% | 27.4% | 36.6% | 47.3% |
| Operating Margin | -116.9% | -116.9% | -337.9% | -596.0% | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% | -244.3% | -311.6% |
| Net Profit Margin | -92.6% | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | -245.8% | -277.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.2% | -66.2% | -170.3% | -134.6% | -45.2% | -38.9% | -212.5% | -433.6% | -182.5% | — | — |
| ROA | -35.1% | -35.1% | -77.0% | -89.1% | -38.7% | -33.1% | -90.7% | -108.4% | -105.9% | -187.4% | -127.5% |
| ROIC | -49.1% | -49.1% | -73.9% | -78.1% | -34.1% | -34.4% | -298.9% | -429.8% | -579.1% | — | — |
| ROCE | -74.1% | -74.1% | -135.3% | -111.5% | -42.0% | -37.9% | -139.3% | -214.5% | -296.5% | — | -390.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.16 | 0.16 | 0.77 | 0.83 | 0.05 | 0.03 | 0.47 | 5.56 | 0.89 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.09 | 0.51 | 0.64 | 0.03 | -0.04 | -0.63 | 0.77 | -0.74 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -111.88 | -111.88 | -386.49 | -44.41 | -437.63 | -83.31 | -14.71 | -12.03 | -12.38 | -38.51 | -39.07 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.98 | 1.98 | 1.06 | 1.40 | 4.38 | 12.47 | 5.23 | 1.07 | 5.09 | 0.43 | 1.15 |
| Quick Ratio | 1.74 | 1.74 | 0.76 | 1.17 | 3.55 | 11.91 | 4.86 | 0.94 | 4.85 | 0.33 | 0.95 |
| Cash Ratio | 0.58 | 0.58 | 0.25 | 0.67 | 3.15 | 11.47 | 4.30 | 0.66 | 3.65 | 0.06 | 0.56 |
| Asset Turnover | — | 0.39 | 0.40 | 0.17 | 0.09 | 0.05 | 0.14 | 0.34 | 0.48 | 0.94 | 0.46 |
| Inventory Turnover | 4.08 | 4.08 | 2.73 | 1.16 | 0.73 | 1.14 | 1.73 | 1.97 | 8.15 | 3.56 | 1.99 |
| Days Sales Outstanding | — | 66.58 | 56.62 | 97.64 | 98.41 | 108.01 | 119.12 | 228.23 | 137.30 | 128.73 | 99.22 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $5M | $2M | $580551 | $491658 | $470530 | $177227 | $424 | $201 | $0 | $0 |
Acute liquidity and dilution
According to current market data, BNGO trades at a price-to-sales multiple of 0.13, which, based on reported figures, suggests that investors are heavily discounting the company's future revenue potential due to persistent operational losses and the significant risk of further equity dilution to fund ongoing research activities.
The extremely low P/S ratio relative to the broader life sciences tools sector indicates that the market has largely abandoned the growth-at-any-cost narrative for this firm. This valuation level implies that the market is pricing in a high probability of financial distress rather than the long-term adoption of the Saphyr platform.
As reported in financial statements, the company's ROIC has remained consistently negative, reaching -13.3% in 2026Q1, which indicates that the capital deployed into the business is currently destroying shareholder value rather than compounding it through the successful commercialization of optical genome mapping technology.
The persistent inability to generate a positive return on invested capital suggests that the cost of maintaining the current R&D and sales infrastructure far outweighs the economic benefits produced by the installed base. Investors should monitor whether future capital allocation shifts toward efficiency, as current trends show a structural decay in capital productivity.
Based on the company's reported figures, the cash conversion cycle has fluctuated significantly, reaching 64 days in 2026Q1, which suggests that management faces ongoing challenges in optimizing inventory turnover and managing the collection of receivables from clinical and research institutions within the diagnostic tools market.
The high variability in the cash conversion cycle, particularly the elevated days inventory outstanding, points to potential inefficiencies in the supply chain or a mismatch between production levels and actual market demand. This volatility complicates cash flow forecasting and highlights the operational friction inherent in scaling a specialized hardware business.
According to recent SEC filings, the company's cash and equivalents have dwindled to approximately $2.99M, a level that appears insufficient to support the current burn rate, thereby increasing the likelihood of near-term financing events that could significantly dilute existing shareholders' equity stakes in the firm.
The current ratio of 1.84 provides a superficial sense of stability, but the absolute cash position is alarmingly low given the magnitude of quarterly operating losses. This liquidity profile suggests that the company is operating with almost no margin for error, making it highly vulnerable to any delays in product adoption or unexpected capital requirements.
While the market often focuses on the growth of the installed base as a primary indicator of success, this metric is frequently misapplied to BNGO because it fails to account for the high cost of customer acquisition and the lack of meaningful consumable pull-through per unit.
Investors should prioritize the consumable pull-through rate over the raw number of Saphyr units placed, as the latter can be misleading if the units are not generating recurring revenue. Relying on the installed base as a proxy for future earnings ignores the reality that without high-margin reagent sales, the hardware footprint remains a liability rather than an asset.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BNGO stock.
Bionano Genomics, Inc.'s current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Bionano Genomics, Inc.'s return on equity (ROE) is -66.2%. The historical average is -160.5%.
Based on historical data, Bionano Genomics, Inc. is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Bionano Genomics, Inc. has 22.0% gross margin and -116.9% operating margin.